US equities
|
MU
$1,083.72
▲+3.65%
SNDK
$1,722.35
▲+3.73%
NVDA
$236.86
▼-0.99%
SPCX
$166.56
▼-3.12%
AMD
$643.89
▼-0.85%
INTC
$112.65
▲+0.13%
TSLA
$376.89
▼-1.00%
AAPL
$336.70
▲+0.92%
MU
$1,083.72
▲+3.65%
SNDK
$1,722.35
▲+3.73%
NVDA
$236.86
▼-0.99%
SPCX
$166.56
▼-3.12%
AMD
$643.89
▼-0.85%
INTC
$112.65
▲+0.13%
TSLA
$376.89
▼-1.00%
AAPL
$336.70
▲+0.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Palvella Therapeutics, Inc. - Common Stock
(NQ:
PVLA
)
130.13
+2.13 (+1.67%)
Delayed Quote
Updated: 1:56 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Palvella Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
September 28, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
September 09, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 02, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
August 31, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track
↗
May 07, 2026
Via
Chartmill
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
↗
August 16, 2026
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN...
Via
MarketBeat
Palvella (PVLA) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy.
Via
The Motley Fool
Topics
Earnings
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 05, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Q2 Earnings Call Highlights
↗
August 04, 2026
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half...
Via
MarketBeat
Topics
Earnings
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
↗
August 04, 2026
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For...
Via
Benzinga
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
June 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
June 29, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
↗
June 27, 2026
Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 03, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 02, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 21, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
May 20, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Q1 Earnings Call Highlights
↗
May 08, 2026
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting...
Via
MarketBeat
Topics
Earnings
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 07, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 04, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 20, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
April 13, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
